Last reviewed · How we verify
NCT02914054
Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone
Phase 2, PHASE3 trial testing High dose Dexamethasone pulses in ITP in 36 participants. Completed in 15 September 2017.
15 September 2017
Quick facts
| Lead sponsor | Isfahan University of Medical Sciences |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 1 October 2016 |
| Primary completion | 15 September 2017 |
| Estimated completion | 15 September 2017 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- High dose Dexamethasone pulses — full drug profile →
- Prednisone (prednisone) — full drug profile →
Conditions studied
- ITP — all drugs for ITP →
- Croticosteroid Therapy — all drugs for Croticosteroid Therapy →
Sponsor
Isfahan University of Medical Sciences
Who can join
18 and older, any sex, with ITP or Croticosteroid Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this prospective, randomized, controlled clinical trial investigators' aim was to compare the efficacy and the adverse effect of 3 therapy cycles of HD-DXM versus conventional treatment with PDN for untreated adult patients with ITP. In this study standardized criteria and definitions were used according to consensus international working group guideline for ITPto compare clinical outcomes of the two corticosteroid treatment regimens and determine the superior regimen as a first line strategy for new primary ITP in adults
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluation of treatment plan by three-period pulses of high-dose dexamethasone among patients with primary immune thrombocytopenia on platelet count response and adverse events: A randomized Clinical trial.
Sadeghi A, Hosseini SF, Jouzdani SR. · · 2020 · cited 6× · PMID 33273933 · DOI 10.4103/jrms.jrms_257_19
Verify or expand the search:
- PubMed search for NCT02914054
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Isfahan University of Medical Sciences trials
Trials by the same sponsor.
- NCT06991933 — Construction and Educational Impact of Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spi · NA · not yet recruiting
- NCT07031960 — 3D Eye Movement Simulator for Medical Education · NA · not yet recruiting
- NCT07195370 — Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma · NA · active not recruiting
- NCT06642363 — The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Pol · Phase 1 · recruiting
- NCT06379659 — Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compare · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02914054 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Isfahan University of Medical Sciences
- Last refreshed: 18 September 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02914054.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing